Avalo Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2022 to Q2 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
-
Summary
-
Avalo Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2022 to Q2 2023.
- Avalo Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending June 30, 2023 was $38K.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)